Evaluation of clinoptilolite and topical tacrolimus efficacy in cd1 mice with 2,4-dinitrofluorobenzene induced atopic dermatitis-like lesion

Atopic dermatitis (AD) is a multifactorial disease process. It is defined as "a genetically predisposed inflammatory and itchy allergic skin disease associated with the production of immunoglobulin (Ig) E against environmental allergens". Induced models are considered important in the evaluation of therapeutic agents for the treatment of AD. It was aimed to reveal the effects of clinoptilolite and tacrolimus on atopic dermatitis lesions in the AD model created with DNFB. For this purpose, clinical score, serum TARC and histopathological and immunohistochemical evaluations of clinoptilolite and tacrolimus were performed. In mice, repeated topical application of 2,4-dinitrofluorobenzene dissolved in acetone has been reported to induce eczematous changes in the skin and cause persistent itching. In our study, mice were administered 0.15% 2,4-dinitrofluorobenzene (DNFB) twice a week for 5 weeks. For the next 4 weeks, 0.15% DNFB was applied once a week to maintain inflammation. This was treated with topical tacrolimus cream (0.1%) and topical clinoptilolite powder for 4 weeks. While clinoptilolite treatment was found to be effective in the normalization of both clinical scores and histopathological values, serum TARC levels were found to be variable. As a result, the anti-inflammatory effect of clinoptilolite was similar to that of tacrolimus.